Drug Database
FL

fluoxetine (EDG005)

✓ Approved

Edgemont Pharmaceuticals, LLC · SLC6A4 · 小分子

什么是 fluoxetine?

fluoxetine 是一种小分子,由Edgemont Pharmaceuticals, LLC研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名EDG005
公司Edgemont Pharmaceuticals, LLC
药物类别小分子
分子靶点SLC6A4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

fluoxetine 作用于 1 个分子靶点:

SLC6A4solute carrier family 6 member 4 (5HTT, 5-HTT)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fluoxetine 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersBulimia nervosa✓ Approved
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Psychiatric disordersPanic disorder✓ Approved
Psychiatric disordersMajor depression✓ Approved

相关研究文献

PubMedJournal of immunology research2026-11-19

Regulatory T and Activated T Cells in the Chronic Unpredictable Mild Stress Mice: Sex Differences and Effects of Treatments.

Niu Mengqi M, Zhang Yingqian Y, Almulla Abbas F AF, Chen Tangcong T et al.

Major depressive disorder (MDD) is associated with immune dysregulation, including T-cell activation and reduced regulatory T cells. Pharmacological treatments like fluoxetine, simvastatin, curcumin, and S-adenosylmethionine (SAMe) show promise in alleviating depressive symptoms, but their effects on immune responses are not fully understood. This study explored immune status in MDD using the chronic unpredictable mild stress (CUMS) mouse model. It examined how fluoxetine, simvastatin, curcumin, and SAMe affected immune responses and depressive behaviors. The study also investigated sex differences. Six groups, each with 12 mice (6 males and 6 females), were included: control, CUMS and drug treatments. Male and female mice were housed separately in sex-specific cages throughout the experiment, with three mice per cage. Behavioral tests included sucrose preference, forced swimming, open field and active avoidance. Immune cell markers were analyzed by flow cytometry. CUMS mice showed immune imbalance, with Treg depletion (p = 0.047) and a higher CD154/CD152 ratio (p = 0.006). All treatments improved depressive-like behaviors (all p < 0.05), with SAMe normalizing the CD154/CD152 ratio (p = 0.009). Furthermore, female mice exhibited lower levels of Treg-related immune regulation and T-cell activation compared to males (both p < 0.001), along with a higher CD154/CD152 ratio (p = 0.008). This study highlights that curcumin, simvastatin, fluoxetine, and SAMe alleviate depressive-like behaviors, while SAMe also reduces the CD154/CD152 ratio. These findings reveal marked sex differences in T-cell activation and immune regulation, highlighting the importance of considering sex as a biological variable in CUMS research.

PMID 43053499
阅读全文 →
PubMedBMC psychiatry2026-11-19

Navigating the diagnostic challenges of maladaptive daydreaming: a case report of ego-syntonic and ego-dystonic obsessive fantasies with functional impairment in a 17-year-old.

Elrashed Mahgoub M, Amin Moustafa M, Joy George V GV, Alsubaiey Maha M

Maladaptive daydreaming (MD) is an emerging and insufficiently recognized clinical phenomenon characterized by immersive fantasy activity associated with functional impairment. Its overlap with obsessive-compulsive disorder (OCD), autism spectrum disorder (ASD), and schizophrenia spectrum conditions creates significant diagnostic uncertainty, particularly in adolescents. We report the case of a 17-year-old female presenting with intrusive celebrity-focused fantasies, sleep disturbance, behavioral regression, social withdrawal, and reduced self-care. She described co-existing ego-syntonic and ego-dystonic obsessive imagery with auditory-like pseudo-hallucinatory experiences. The Maladaptive Daydreaming Scale (MDS-16) score was 76%, consistent with probable MD. Extensive medical and neuroimaging investigations were unremarkable. Differential diagnoses included OCD, schizotypal traits, ASD, and schizophrenia prodrome. Initial treatment with fluoxetine was changed to quetiapine, alongside cognitive behavioral therapy, occupational therapy, structured behavioral strategies, and family psychoeducation. The patient demonstrated gradual improvement in distress, insight, sleep, and engagement, although intrusive fantasies persisted. This case highlights the complexity of distinguishing MD from other psychiatric conditions in adolescents and supports the value of a multidisciplinary, function-focused management approach. Early recognition may prevent misdiagnosis and inappropriate treatment. Not applicable.

PMID 43052893
阅读全文 →
PubMedJournal of forensic sciences2026-11-17

Detection of furosemide, sibutramine, and/or fluoxetine adulteration in "all natural" weight loss consumer products at an international mail facility satellite laboratory using handheld/portable rapid screening instruments.

Thatcher Michael D MD, Hill Hannah E HE, Marseille Marie M, Reimer Allison M AM et al.

A total of 97 consumer products claiming to be "all natural" or providing label graphics indicating potential weight-loss effects, were examined by a US Food and Drug Administration (FDA) National Forensic Chemistry Center (NFCC) International Mail Facility (IMF) satellite laboratory. All products were examined using a toolkit consisting of a handheld Raman spectrometer, portable Fourier-transform infrared (FT-IR) spectrometer, portable ambient ionization direct analysis in real-time mass spectrometer (DART-MS), and/or portable gas chromatography-mass spectrometry (GC-MS) instrument. Conclusive results were achieved for 89 out of 97 products using the satellite laboratory toolkit only. The remaining eight products were sent to the NFCC full-service laboratory for additional analysis using liquid chromatography with mass spectrometry (LC-MS). All 97 products were found to be adulterated with active pharmaceutical ingredients (APIs), with each containing at least two of the following drugs: furosemide, sibutramine, and/or fluoxetine. Furosemide and fluoxetine are only available with a prescription and sibutramine is a Schedule IV controlled substance. Furthermore, sibutramine, fluoxetine, and furosemide are all under the scope of section 801(u) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and therefore have been identified by FDA as a significant public health risk. Overall, the results of this study helped prevent over 24,000 adulterated consumer product capsules from reaching unsuspecting American consumers during a two-year timeframe.

PMID 43040942
阅读全文 →
PubMedFrontiers in pharmacology2026-11-17

Real-world pharmacovigilance analysis of adverse events associated with selective serotonin reuptake inhibitor antidepressants in children and adolescents.

Yuan Wenjun W, Zhang Fu F, Sun Kexin K, Guo Xiaotong X et al.

Depressive disorders are common in children and adolescents, with major depression affecting 3.7% of youth and subclinical symptoms affecting over one-fifth. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, sertraline, and fluvoxamine, are prescribed for moderate-to-severe pediatric depression. However, real-world safety signals for specific SSRIs remain incompletely characterized because evidence derives mainly from randomized controlled trials with restrictive inclusion criteria, observational studies affected by prescribing bias, and spontaneous reporting systems without reliable exposure denominators. We extracted reports from the U.S. Food and Drug Administration Adverse Event Reporting System through the second quarter of 2026 for depressed children and adolescents aged 6-18 years receiving fluoxetine, sertraline, or fluvoxamine. Disproportionality analyses used reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker to detect signals at system organ class and preferred term levels. Weibull models assessed time to onset, and network toxicology approaches explored candidate targets and pathways underlying the shared rhabdomyolysis signal. A total of 2,614 reports were included: 1,260 for fluoxetine, 1,278 for sertraline, and 76 for fluvoxamine. Psychiatric and nervous system disorders were the most frequently reported system organ classes for all three drugs. Fluoxetine showed prominent signals for serotonin syndrome, neuroleptic malignant syndrome, rhabdomyolysis, blood creatine phosphokinase increase, and acute kidney injury; sertraline showed strong signals for serotonin syndrome, urinary retention, intentional self-injury, rhabdomyolysis, hepatocellular injury, and respiratory failure. Rhabdomyolysis was reported in 39 fluoxetine cases (ROR = 4.26, 95% CI: 2.81-6.45) and 26 sertraline cases (ROR = 2.69, 95% CI: 1.71-4.24). Time-to-onset analyses revealed an early-failure Weibull pattern for both drugs, with median onsets of 24 and 30 days, respectively. Network toxicology analysis identified shared candidate targets including CYP3A4, CYP2D6, SLC6A4, MAOA, DRD1, DRD2, NOS2, and KCNH2, with enrichment in serotonergic synapse, oxidative stress, and hypoxia response pathways. This study provides evidence to prioritize symptoms, organ systems, and high-risk monitoring windows in pediatric SSRI prescribing. It offers the first systematic report of SSRI-associated rhabdomyolysis in children and adolescents and translates real-world pharmacovigilance signals into guidance for baseline risk assessment, early monitoring, family education, and symptom-driven laboratory testing.

PMID 43041555
阅读全文 →
PubMedInternational immunopharmacology2026-11-16

Rotigotine Behenate ameliorates depression in Parkinson's disease through NF-κB-mediated anti-inflammation and BDNF-mediated neuroprotection.

Wu Mengting M, Yin Zhicong Z, Chen Yumeng Y, Qin Caiyi C et al.

Depression in Parkinson's disease (DPD) is a prevalent non-motor complication that currently lacks effective targeted therapy. We established a combined MPTP/CUMS model in male C57BL/6 mice, which induced a higher incidence of depression and more stable depressive-like phenotypes than MPTP-only modeling and closely recapitulated clinical DPD pathology. Pearson correlation analysis confirmed severe dopamine (DA) and 5-hydroxytryptamine (5-HT) dysregulation predominantly in the striatum (STR) and prefrontal cortex (PFC), identifying these regions as core DPD lesion sites. Behavioral assays demonstrated that ROTB ameliorated both motor dysfunction and depressive-like behavior and restored regional neurotransmitter balance, whereas fluoxetine-included solely as an efficacy comparator for the depressive-like phenotype-did not improve motor symptoms. Mechanistically, ROTB suppressed NF-κB/NLRP3-mediated neuroinflammation and activated the BDNF/TrkB/PI3K/Akt/GSK-3β cascade, elevating synaptic protein levels and reversing dendritic spine loss. Pharmacological inhibition of the NF-κB pathway with QNZ only partially recapitulated the antidepressant effects of ROTB, indicating the existence of NF-κB-independent protective mechanisms. In summary, ROTB alleviates DPD through NF-κB-mediated anti-inflammation and BDNF-mediated neuroprotection, offering preclinical evidence for DPD therapy.

PMID 43035072
阅读全文 →
PubMedPsychotherapy and psychosomatics2026-11-16

Concomitant Psychotropic Medication Is Associated with Reduced Outcomes of Trauma-Focused Psychotherapy for Post-Traumatic Stress Disorder.

Steenen Serge A SA, van Westrhenen Roos R, Steenen Camilo C CC, Klausch L Thomas LT et al.

Psychotropic medications are frequently prescribed alongside trauma-focused psychotherapy for post-traumatic stress disorder (PTSD), yet their impact on treatment response remains uncertain. This study emulated target trials to examine the association between psychotropic co-medication at treatment onset and psychotherapy outcomes in a real-world PTSD cohort. A prospective cohort of 6,125 adults with chronic or delayed-onset PTSD received a standardized 2-8 day trauma-focused psychotherapy program, including daily prolonged exposure and eye movement desensitization and reprocessing (EMDR) therapy, at a Dutch psychotrauma center (2021-2024). Target trial emulation with double machine learning with inverse probability of treatment weighting estimated the effects of specific psychotropic co-medications versus non-use on changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores (range, 0-80) from pre-to post-treatment. Mean CAPS-5 scores improved by 25.7 points (Cohen's d = -2.30). Psychotropic co-medication (n = 1,382) was associated with reduced symptom improvement compared with non-use (model-estimated difference = -2.52 points; relative reduction = -9.4%, 95% CI = -10.0 to -8.9; d = -1.11, E = 10.0). This effect persisted at 6-month follow-up (d = -0.42). Antidepressants overall (d = -0.28; follow-up d = -0.56), amitriptyline (d = -0.51), and mirtazapine (d = -0.29) were consistently associated with poorer outcomes across sensitivity analyses. Similar patterns were observed for anticonvulsants, mood-stabilizing anticonvulsants, antipsychotics, fluoxetine, zolpidem, and zopiclone. Sensitivity analyses and E-values indicated robustness to unmeasured confounding. Several psychotropic co-medications were associated with reduced outcomes of evidence-based trauma-focused psychotherapy for PTSD. By identifying this as a potentially modifiable factor, psychotherapy outcomes may be optimized. Trials are warranted to evaluate whether tapering or substituting these agents improves outcomes.

PMID 43038311
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fluoxetine